Product Information
XCOPRI 150-200 MG TITRATION PK is a brand product labeled by SK Life Science, Inc., priced at $42.9098 per EA under NDC 71699020328. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Mar 10, 2020.
Manufacturer
SK Life Science, Inc.NDC
71699020328
Classification
Brand
Dosage Form
KIT
Route
ORAL
Effective Date
9/23/2026
Approval Type
New Drug (NDA)
FDA Application
NDA212839FDA Approved
3/10/2020
On Market Since
3/12/2020
Price Statistics
The NADAC for XCOPRI 150-200 MG TITRATION PK has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 5.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $42.9098 per EA |
|---|---|
| All-time high | $42.9889 (Sep 16, 2026) |
| All-time low | $40.5065 (Dec 18, 2024) |
| 52-week high | $42.9889 |
| 52-week low | $41.3417 |
| Median price | $41.4601 |
| Average price | $41.6080 |
| Largest weekly change | +3.0% (Jan 7, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 91% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
SK Life Science, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cenobamate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XCOPRI 150-200 MG TITRATION PK?
The current National Average Drug Acquisition Cost (NADAC) for XCOPRI 150-200 MG TITRATION PK, manufactured by SK Life Science, Inc., is $42.9098 per EA (NDC 71699020328), effective Sep 30, 2026.
How has the price of XCOPRI 150-200 MG TITRATION PK changed over time?
Over the history we have for it, the NADAC for XCOPRI 150-200 MG TITRATION PK has risen 5.5%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for XCOPRI 150-200 MG TITRATION PK?
Since Apr 17, 2024, the NADAC for XCOPRI 150-200 MG TITRATION PK has ranged from a low of $40.5065 (Dec 18, 2024) to a high of $42.9889 (Sep 16, 2026), with a median of $41.4601 per EA.
Are there cheaper alternatives to XCOPRI 150-200 MG TITRATION PK?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, XCOPRI 12.5-25 MG TITRATION PK, is $3.9104 per EA — about 91% below XCOPRI 150-200 MG TITRATION PK.
Who manufactures XCOPRI 150-200 MG TITRATION PK?
XCOPRI 150-200 MG TITRATION PK (NDC 71699020328) is labeled by SK Life Science, Inc., and CMS classifies it as a brand product.